{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:03:22Z","timestamp":1772777002776,"version":"3.50.1"},"reference-count":16,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologica"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Aims: The aim of the study was to investigate non-persistence with treatment for neovascular age-related macular degeneration (NvAMD) before day 720 (24 months) after initiation, explore associations with baseline characteristics and variation between sites. Methods: Anonymised demographic and clinical data were extracted from electronic medical records at treating National Health Service (NHS) Trusts for NvAMD eyes starting intra-vitreal therapy from 2017 to 2018. Time to non-persistence with treatment, defined as no recorded attendance for either monitoring or treatment for a period \u22656 months, was visualised with a Kaplan-Meier survival plot. Associations with treatment non-persistence were investigated using a Cox proportional hazards model. Results: Analysis included 7,970 eyes of 7,112 patients treated at 13 NHS trusts. Censoring deaths and those eyes in which treatment was stopped permanently, the Kaplan-Meier analyses demonstrated survival figures of 77.7% for persistence with treatment to day 360 and 71.8% to day 720. Hazard ratios for non-persistence with treatment were reduced at 10 sites, relative to the reference, with first-treated eye status and with baseline acuity worse than or equal to LogMAR 1.0. Hazard ratios increased with younger age, in the presence of other ocular co-morbidities and with baseline acuity better than or equal to LogMAR 0.5. After an episode of non-persistence, visual acuity decreased by at least 0.1 and 0.3 LogMAR in 39% and 18% of eyes, respectively. Conclusions: Non-persistence with treatment was common, especially in the first year of treatment, and was often associated with a decrease in visual acuity. Treatment site, baseline visual acuity, and age were the strongest predictors of treatment non-persistence before day 720. Understanding and addressing reasons for non-persistence are important to ensure that effective but expensive treatments are used cost-effectively and to maintain acuity. Variation in non-persistence between sites, even after adjustment for other variables, suggests that local factors in treatment provision may be particularly important. <\/jats:p>","DOI":"10.1159\/000529446","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T22:00:37Z","timestamp":1675720837000},"page":"90-98","source":"Crossref","is-referenced-by-count":2,"title":["Associations with Non-Persistence with Intra-Vitreal Therapy for Neovascular Age-Related Macular Degeneration at 24 Months"],"prefix":"10.1159","volume":"246","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0634-4587","authenticated-orcid":false,"given":"Samuel D","family":"Relton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria C","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Lotery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-3654","authenticated-orcid":false,"given":"Robert M","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-243X","authenticated-orcid":false,"given":"Martin","family":"McKibbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Real-world AMD treatment outcomes EMR User Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-308166"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305327"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S151611"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.1660"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04798-2"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.060"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.86"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001681"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189035"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.3578"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S293941"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-01957-z"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.07.010"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001494"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3739-1"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13233"}],"container-title":["Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/oph\/article-pdf\/246\/2\/90\/3958613\/000529446.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/oph\/article-pdf\/246\/2\/90\/3958613\/000529446.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:13:30Z","timestamp":1745421210000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000529446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,7,14]]},"published-print":{"date-parts":[[2023,7,18]]}},"URL":"https:\/\/doi.org\/10.1159\/000529446","archive":["Portico"],"relation":{},"ISSN":["0030-3755","1423-0267"],"issn-type":[{"value":"0030-3755","type":"print"},{"value":"1423-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}